Joseph Grossman, Vice President of Early Clinical Development at Agenus, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Journal for ImmunoTherapy of Cancer:
“I’m proud to share our new paper in Journal for ImmunoTherapy of Cancer reporting clinical results with botensilimab (Fc-enhanced anti-CTLA-4) plus balstilimab (anti-PD-1) in women with treatment-refractory ovarian cancer.
I’m grateful to the patients and families who participated, and to the investigators and study teams who made this work possible. I’m also thankful to the authors and investigators including Rebecca Porter, Bruno Bockorny, Ursula Matulonis, Michael Gordon, and hopeful as always that effective immunotherapy will lead to long-term survival for more patients.”
Title: Botensilimab (Fc-enhanced anti–CTLA-4 antibody) plus balstilimab (anti–PD-1 antibody) in patients with treatment-refractory ovarian cancer
Authors: Rebecca Porter, Bruno Bockorny, Bradley R. Corr, Daruka Mahadevan, Breelyn A. Wilky, Anthony B. El-Khoueiry, Andrea J. Bullock, Navid Hafez, Justin Moser, Anastasia Martynova, Justin Stebbing, Bishnu Joshi, Sean Bourdelais, Chloe Delepine, Dhan Chand, Wei Wu, Benny Johnson, Joseph E. Grossman, Steven J. O’Day, Ursula A. Matulonis, Michael S. Gordon
Read the Full Article on Journal for ImmunoTherapy of Cancer
More posts featuring Joseph Grossman.